Business
ANI Announces Launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL
BAUDETTE, Minn., Feb. 12, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Sulfamethoxazole and
About this update from Ani Pharmaceuticals, Inc.
[{"type":"text","content":"BAUDETTE, Minn., Feb. 12, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (\"ANI\") (Nasdaq: ANIP) today announced the launch of Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL. The current annual market for this product is approximately $29 million, according to IQVIA. This launch represents ANI's third generic product introduction in 2020.\nArthur S. Przybyl, ANI's President and CEO commented, \"This is the twelfth product that ANI has successfully launched from our library of discontinued NDAs and ANDAs. This library now includes 118 generic products, 52 of which can be launched via a CBE-30 or prior approval supplement filing. We continue to selectively re-commercialize products from this library that can provide economic value and, when possible, leverage our internal manufacturing capabilities.\"\nAbout Sulfamethoxazole and Trimethoprim Oral Suspension USP 200 mg/40 mg per 5 mL \nSulfamethoxazole and Trimethoprim Oral Suspension is indicated in the treatment and prevention of various infections proven or strongly suspected to be caused by susceptible bacteria which include urinary tract infections, acute otitis media, bronchitis, shigellosis, Pneumocystis jiroveci pneumonia, and traveler's diarrhea. For more information, including the complete list of indications and usages, please see the Full Prescribing Information.\nAbout ANI\nANI Pharmaceuticals, Inc. (the \"Company\" or \"ANI\") is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company's targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website www.anipharmaceuticals.com.\nForward-Looking Statements \nTo the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company's future operations, products, financial position, operating results and prospects , the Company's pipeline or potential markets therefor, and other statements that are n...